EuroBiotech: More Articles of Note


> Sanfit wrapped up enrollment in a phase 2b clinical trial of its treatment for cardiovascular calcification in patients with end-stage renal disease. The Spanish biotech expects to have data in the second half of next year. Statement 

> Hansa Medical began an observational follow-up study to track the long-term performance of kidney transplant patients who received its antibody-depletion enzyme in a midphase trial. Release

> ADC Therapeutics dosed the first patient in a phase 2 diffuse large B-cell lymphoma trial. The deep-pocketed Swiss biotech hopes the trial will generate data to support a filing for approval in the U.S. Statement 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Bavarian Nordic reported positive data from an extension to its phase 2 respiratory syncytial virus vaccine trial. The data tee Bavarian Nordic up to talk to regulators about a phase 3 trial later in the year. Release 

> Silence Therapeutics shared an update on its patent dispute with Alnylam. Statement